| Entry |
|
|---|
| Name |
Fluvastatin (INN);
Fluvas (TN) |
|---|
| Formula |
C24H26FNO4
|
|---|
| Exact mass |
411.1846
|
|---|
| Mol weight |
411.4659
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Hypolipidemic agent
DG01946 Hypolipidemic agent
DG01660 HMG-CoA reductase inhibitor
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
Metabolizing enzyme inhibitor
DG01643 CYP2C9 inhibitor
Transporter substrate
DG02856 SLCO1B1 substrate
Transporter inhibitor
DG02882 ABCB11 inhibitor
|
|---|
| Remark |
| Product (DG00354): | D00892<JP/US> |
|
|---|
| Efficacy |
Antihyperlipidemic, HMG-CoA reductase inhibitor |
|---|
| Target |
|
|---|
| Pathway |
| hsa00900 | Terpenoid backbone biosynthesis |
|
|---|
| Metabolism |
Enzyme: CYP2C9 [HSA: 1559], CYP3A4 [HSA: 1576]
Transporter: SLCO1B1 [HSA: 10599]
|
|---|
| Interaction |
CYP inhibition: CYP2C9 [HSA: 1559]
Transporter inhibition: ABCB11 [HSA: 8647]
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C10 LIPID MODIFYING AGENTS
C10A LIPID MODIFYING AGENTS, PLAIN
C10AA HMG CoA reductase inhibitors
C10AA04 Fluvastatin
D07983 Fluvastatin (INN)
Drug groups [BR:br08330]
Hypolipidemic agent
DG01946 Hypolipidemic agent
DG01660 HMG-CoA reductase inhibitor
DG00354 Fluvastatin
D07983 Fluvastatin
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG00354 Fluvastatin
D07983 Fluvastatin
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00354 Fluvastatin
D07983 Fluvastatin
Metabolizing enzyme inhibitor
DG01643 CYP2C9 inhibitor
DG00354 Fluvastatin
D07983 Fluvastatin
Transporter substrate
DG02856 SLCO1B1 substrate
DG00354 Fluvastatin
D07983 Fluvastatin
Transporter inhibitor
DG02882 ABCB11 inhibitor
DG00354 Fluvastatin
D07983 Fluvastatin
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
HMGCR
D07983 Fluvastatin (INN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D07983
Drug transporters
D07983
Drug groups [BR:br08330]
Hypolipidemic agent
DG01946 Hypolipidemic agent
DG01660 HMG-CoA reductase inhibitor
DG00354 Fluvastatin
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG00354 Fluvastatin
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00354 Fluvastatin
Metabolizing enzyme inhibitor
DG01643 CYP2C9 inhibitor
DG00354 Fluvastatin
Transporter substrate
DG02856 SLCO1B1 substrate
DG00354 Fluvastatin
Transporter inhibitor
DG02882 ABCB11 inhibitor
DG00354 Fluvastatin
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 30
1 C8y C 20.9855 -16.8573
2 C8x C 20.9855 -18.2563
3 C8x C 22.1746 -18.9557
4 C8y C 23.4336 -18.2563
5 C8x C 23.4336 -16.8573
6 C8x C 22.1746 -16.1579
7 X F 19.7964 -16.1579
8 C8y C 24.6227 -18.9557
9 C8y C 25.1123 -20.2847
10 C8y C 26.4413 -20.2847
11 N4y N 26.8610 -18.9557
12 C8y C 25.7418 -18.1164
13 C8x C 24.4129 -21.5437
14 C8x C 25.1123 -22.8028
15 C8x C 26.5113 -22.8028
16 C8x C 27.2107 -21.5437
17 C2b C 25.7418 -16.7174
18 C1a C 29.3091 -18.9557
19 C1c C 28.1200 -18.2563
20 C1a C 28.1200 -16.8573
21 C2b C 26.9309 -16.0180
22 C1c C 26.9309 -14.6191
23 C1b C 28.1200 -13.9196
24 C1c C 29.3091 -14.6191
25 C1b C 30.4982 -13.9196
26 C6a C 31.6873 -14.6191
27 O6a O 32.8764 -13.9196
28 O6a O 31.6873 -16.0180
29 O1a O 25.7418 -13.9196
30 O1a O 29.3091 -16.0180
BOND 32
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 1 7 1
8 4 8 1
9 8 9 1
10 9 10 1
11 10 11 1
12 11 12 1
13 8 12 2
14 9 13 2
15 13 14 1
16 14 15 2
17 15 16 1
18 10 16 2
19 12 17 1
20 18 19 1
21 11 19 1
22 19 20 1
23 17 21 2
24 21 22 1
25 22 23 1
26 23 24 1
27 24 25 1
28 25 26 1
29 26 27 1
30 26 28 2
31 22 29 1 #Down
32 24 30 1 #Up
|
|---|
